Donepezil in the treatment of patients with Alzheimer’s disease

References

• Eggert A, Crismon ML, Ereshefsky L. Alzheimer's disease. In: Pharmacotherapy (3rd Edition). Dipiro J, Talbert RL, Yee GC (eds). Elsevier, New York, USA 1325–1344 (1997).
   Google Scholar
• Fratiglioni L, Launer L,J, Andersen K et al. for the Neurologic Diseases in the Elderly Research Group. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology54\(Suppl. 5), S10-S15 (2000).
   Google Scholar
• Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl. j Med. 341, 1670–1679 (1999).
   PubMed Web of Science ®Google Scholar
• Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The consortium to establish a registry for Alzheimer's disease (CERAM Part XI Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology45, 1451–1455 (1995).
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in patients with Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 2), S33—S39 (1997).
   Google Scholar
• Schmeidler J, Mohs RC, Aryan M. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer's disease. Alzheimer Dis. Assoc. Disord 12,146–151 (1998).
   PubMed Web of Science ®Google Scholar
• Green CR, Mann DB, Mohs RC eta]. The impact of behavioral impairment of functional ability in Alzheimer's disease. int. J Gerian: fiychiatry14, 307–316 (1999).
   Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403 (1976).
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408–417 (1982).
   PubMed Web of Science ®Google Scholar
• Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BIl/1J2, 1457–1459 (1978).
   Google Scholar
• Lawrence AD, Sahakian BJ. Alzheimer's disease, attention and the cholinergic system. Alzheimer Dis. Assoc. Disord. 9\(Suppl. 2), 43–49 (1995).
   Google Scholar
• Beach TG, Kuo YM, Spiegel K et al. The cholinergic deficit coincides with A-beta deposition at the earliest histopathologic stages of Alzheimer's disease. J Neuropathol. Exp. Neurol. 59, 308–313 (2000).
   PubMed Web of Science ®Google Scholar
• Näslund J, Haroutunian V, Mohs R, Davis KL, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid13-peptide in the brain and cognitive deficits. JAMA 283, 1571–1577 (2000).
   Google Scholar
• Drachman Leavitt J. Human memory and the cholinergic system: a relationship to aging. Arch. Neurol. 30, 113–121 (1974).
   PubMedGoogle Scholar
• Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am. J Geriatric Psychiatry 6 (Suppl. 6), S64—S78 (1998).
   Google Scholar
• Giacobini E (ed.). Cholinesterases and cholinesterase inhibitors. Martin Dunitz Ltd., London, UK (2000).
   Google Scholar
• Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 15, 85–91 (2001).
   PubMed Web of Science ®Google Scholar
• Gauthier S (ed). Pharmacotherapy of Alzheimer disease. Martin Dunitz Ltd., London, UK (1998).
   Google Scholar
• Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI and the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271, 985–991 (1994).
   Google Scholar
• Becker R, Markwell JA, Moriearty, SJ, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 10, 124–131 (1996).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Yamanishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In: Cholinergic Basis for Alzheimer Therapy Becker R, Giacobini E (eds.), Birkhäuser, Boston, USA, 314–320 (1991).
   Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease. Int. J Geriatr. Psychopharmacol. 1, 55–65 (1998).
   Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 3. Update Software, Oxford, UK (2001).
   Google Scholar
• ••Systematic Cochrane review on rivastigmine.
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W and the Galantamine USA-Study Group. Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6-month extension. Neurology 54 2261–2268 (2000).
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 3. Update Software, Oxford, UK (2001).
   Google Scholar
• ••Systematic Cochrane review on galantamine.
   Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and digoxin: assessment of pharmacokinetic changes. Br. J Clin. Pharmacol. 46\(Suppl. 1), 40–44 (1998).
   Google Scholar
• Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HC1 on the pharmacokinetic and pharmacodynamic profile of warfarin. Br. Clin. Pharmacol. 46\(Suppl. 1), 45–50 (1998).
   Google Scholar
• Nagy CE Latimer FE, Kumar D et al. A multiple-dose study of the pharmacokinetics of donepezil and sertraline in healthy volunteers. Eur. Neuropsychopharmacol. 10\(Suppl. 3), S367, P4.031 (2000).
   Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br. J Clin. Pharmacol. 46\(Suppl. 1), 25–29 (1998).
   Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br. J Clin. Pharmacol. 46\(Suppl. 1), 30–34 (1998).
   Google Scholar
• Homma A, Imai Y, Hagiguchi S, Hasegawa K, Kameyama M, Nishimura T. Late Phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer type dementia. Clin. Evaluation 26, 251–284 (1998).
   Google Scholar
• Burns A, Rossor M, Hecker J et al. and the International Donepezil Study Group. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Dis. 10, 237–244 (1999).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group. Dementia 7, 293–303 (1996).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. 158, 1021–1031 (1998).
   Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 136–145 (1998).
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State.' A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr. Res. 12, 189–198 (1975).
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J Psychiatry141,1356–1364 (1984).
   Google Scholar
• Brooks JO, Yesavage JA, Taylor J et al. Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int. Psychogeriatr. 5, 135–146 (1993).
   PubMedGoogle Scholar
• Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer's type: a comparison of 3 standardized mental status examinations. Neurology 40, 1225–1230 (1990).
   PubMed Web of Science ®Google Scholar
• Stern RG, Mohs RC, Davidson M et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am. .1. Psychiatry 151,390–396 (1994).
   Google Scholar
• Tariot P, Perdomo CA, Whalen E, Sovel MA, Scham EM. Age is not a barrier to donepezil treatment of Alzheimer's disease in the long-term care setting. Int. Psychogeriatr. 11,134 (1999).
   Google Scholar
• Meadows ME, Sperling RA, Growdon JH et al. Donepezil therapy in clinical practice a randomized cross-over study. Arch. NeuroL 57, 94–99 (2000).
   PubMedGoogle Scholar
• Winblad B, Engedal K, Soininen H et al. and the Donepezil Nordic Study Group. Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild-to-moderate Alzheimer's disease. Int. Psychogeriatr.11\(Suppl. 1), 138 (1999).
   Google Scholar
• Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 2. Update Software, Oxford, UK, (2001).
   Google Scholar
• •• Systematic Cochrane review on donepezil.
   Google Scholar
• Knopman DS, Knapp MJ, Gracon SI, Davis LS. The Clinician Interview-Based Impression (CIBI): A Clinician's global change rating scale in Alzheimer's disease. Neurology 44, 2315–2321 (1994).
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566–572 (1982).
   Google Scholar
• Morris J. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993).
   PubMed Web of Science ®Google Scholar
• Mihara M, Ohnishi A, Tomono Y et a/. Pharmacokinetics of E2020, a new compound for Alzheimer's disease in healthy male volunteers. Int. .1. Clin. PharmacoL Ther ToidcoL 31,223–229 (1993).
   Google Scholar
• Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer's disease: Eighteen months results from Southhampton memory clinic. Int. .1. Geriatr. Psychiatry15,713–720 (2000).
   Google Scholar
• McRae TD, Relkin N, Knopman D. A large-scale trial of donepezil in the treatment of Alzheimer's disease. Neurology 34 (Suppl. 4), A90 :P 02.017 (1998).
   Google Scholar
• Kaufer DI, Catt K, Pollock BG, Lopez OM, DeKosky ST. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 50, A89 (1998).
   Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44,2308–2314 (1994).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J eta]. A 24- week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer's disease. Neurology57,613–621 (2001).
   Google Scholar
• •Paper documenting efficacy of donepezil in moderate-to-severe Alzheimer's disease.
   Google Scholar
• Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int. Psychogeriatr. 12,389–401 (2000).
   Google Scholar
• Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioural disturbances in patients with Alzheimer's disease. Am. .1. Geriatr. Psychiatry8, 134–140 (2000).
   Google Scholar
• Tariot P, Cummings J, Katz I et al. and the Donepezil nursing home study investigators group. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. .1. Am. Geriatr Soc. (In Press).
   Google Scholar
• Panisset M, Feldman H, Gauthier S et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate-to-severe Alzheimer's disease. NeurobioL Aging, 21 (Suppl. 1), S94 (426), (2000).
   Google Scholar
• Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate-to-severe Alzheimer's disease. NeurobioL Aging 21\(Suppl. 1),S161(733) (2000).
   Google Scholar
• Hecker J, Foti D, Gauthier S, Vellas B, Subbiah P, Whalen E. Benefits of donepezil in the treatment of behavioral problems in moderate-to-severe Alzheimer's disease. NeurobioL Aging 21 (Suppl. 1), 5162 (734) (2000).
   Google Scholar
• Rogers SL, Doody RS, Pratt RD, kni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur NeuropsychopharmacoL 10, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD and the Donepezil study group. Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch. NeuroL 58,427–433 (2001).
   Google Scholar
• •Paper on long-term open-label study of donepezil.
   Google Scholar
• Winblad B, Engedal K, Soininen H eta], and the Donepezil Nordic Study Group. A 1-year randomized, placebo-controlled study of donepezil in patients with mild-to-moderate AD. Neurology 57, 490–496 (2001).
   Google Scholar
• ••Long-term placebo-controlled study ondonepezil.
   Google Scholar
• Mohs R, Doody R, Morris J et al. for the
   Google Scholar
• ' Study Group. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology2001, 57, 481-489 (2001).
   Google Scholar
• •Study showing that donepezil delays time to clinically significant functinal decline.
   Google Scholar
• Waldemar G, Winblad B, Engedal K et al. and the Donepezil Nordic Study Group. Benefits of donepezil on cognition, function and neuropsychiatric symptoms in patients with mild and moderate Alzheimer's disease over one year. In: Iqbal K, Sisodia SS, Winblad B, (eds). Alzheimer.i disease: Advances in Etiology Pathogenesis and Therapeutics. Wiley & Sons, New York, USA, 725–738 (2001).
   Google Scholar
• Gottfries CG, Beane G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch. GerontoL Geriatr. 1,311–330 (1982).
   PubMedGoogle Scholar
• Beane G, Gottfries CG, Winblad B. The Gottfries-Brine-Steen (GBS) scale: validity, reliability and application in antidementia drug trials. Dementia Geriatr. Cognitive Dis. 12,1-14 (2001).
   Google Scholar
• DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin. Therapeutics ii, 545–554 (1989).
   Google Scholar
• Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis. Assoc. Disord. 13\(Suppl. 2), S9—S19 (1999).
   Google Scholar
• Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer's disease. Pharmacotherapy 18, 68–73 (1998).
   Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52, 1138–1145 (1999).
   PubMed Web of Science ®Google Scholar
• Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin. Ther. 21, 1230–1241 (1999).
   Google Scholar
• Lovestone S, Gauthier S. Management of dementia. Martin Dunitz Ltd., London, UK (2001).
   Google Scholar
• Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and management of Alzheimer's disease and related disorders: The role of neurologists in Europe. Eur: Neurol. 7, 133–144 (2000). Management guideline.
   Google Scholar
• Doody RC, Stevens JC, Beck RN et al. Practice parameter: Management of dementia (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 56,1154–1166 (2001).
   PubMed Web of Science ®Google Scholar
• ••Management guideline.
   Google Scholar
• Rabins PV, Kasper J. Measuring quality of life in dementia: conceptual and practical issues. Alzheimer Dis. Assoc. Dis. 11 (Suppl. 6), 100–104 (1997).
   Google Scholar
• Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia : Mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 56,1133–1142 (2001).
   PubMed Web of Science ®Google Scholar
• ••Management guideline.
   Google Scholar
• Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 56, 1143–1153 (2001).
   PubMed Web of Science ®Google Scholar
• •• Management guideline.
   Google Scholar
• Nordberg A, Giacobini E (eds.). Alzheimer's disease and future therapy. Acta Neurol. Scand. 102\(Suppl. 176), 1–99 (2000).
   Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179–186 (1969).
   PubMed Web of Science ®Google Scholar